Ruth G Perez

List of Publications by Year
in descending order

37 papers	1,961 citations	257450 24 h-index	330143 37 g-index
37 all docs	37 docs citations	37 times ranked	2764 citing authors

#	Article	IF	Citations
1	Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimerâ€™s Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction. Current Alzheimer Research, 2021, 18, 1010-1022.	1.4	12
2	A Pilot Microbiota Study in Parkinsonâ€™s Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models. Journal of Parkinson's Disease, 2020, 10, 185-192.	2.8	32
3	FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. Experimental Neurology, 2020, 325, 113120.	4.1	16
4	Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease. Frontiers in Neuroscience, 2020, 14, 116.	2.8	8
5	Sphingosineâ€1â€phosphate receptorâ€independent lung endothelial cell barrier disruption induced by FTY720 regioisomers. Pulmonary Circulation, 2020, 10, 1-10.	1.7	8
6	FTY720-Mitoxy reduces toxicity associated with MSA-like Î±-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures. Neuropharmacology, 2019, 158, 107701.	4.1	11
7	FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces Î±-Synuclein Pathology in Parkinsonian GM2 +/â^' Mice. Neuroscience, 2019, 411, 1-10.	2.3	31
8	Up-regulation of protective neuronal MicroRNAs by FTY720 and novel FTY720-derivatives. Neuroscience Letters, 2019, 690, 178-180.	2.1	19
9	Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder. Experimental Neurology, 2019, 311, 265-273.	4.1	8
10	Could Î±-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinsonâ€™s Disease and Diabetes as Well as Potential Therapies?. Frontiers in Molecular Neuroscience, 2018, 11, 465.	2.9	11
11	FTY720 (Fingolimod) reverses Î±-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells. Neuropharmacology, 2017, 117, 149-157.	4.1	27
12	FTY720-derivatives do not induce FTY720-like lymphopenia. Journal of Pharmacological Sciences, 2017, 133, 187-189.	2.5	10
13	FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models. Neurochemical Research, 2017, 42, 686-696.	3.3	55
14	Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays. Journal of Visualized Experiments, 2017, , .	0.3	7
15	Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy. PLoS ONE, 2016, 11, e0162162.	2.5	8
16	FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice. Journal of Biological Chemistry, 2016, 291, 20811-20821.	3.4	62
17	The contribution of alpha synuclein to neuronal survival and function â€“ Implications for Parkinson's disease. Journal of Neurochemistry, 2016, 137, 331-359.	3.9	186
18	Cholinesterase Inhibitor Therapy in Alzheimerâ€™s Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates. Journal of Alzheimer's Disease, 2016, 55, 1285-1294.	2.6	34

#	Article	IF	Citations
19	Sâ€allyl cysteine activates the Nrf2â€dependent antioxidant response and protects neurons against ischemic injury in vitro and in vivo. Journal of Neurochemistry, 2015, 133, 298-308.	3.9	78
20	Nonâ€motor parkinsonian pathology in aging A53T Î±â€synuclein mice is associated with progressive synucleinopathy and altered enzymatic function. Journal of Neurochemistry, 2014, 128, 536-546.	3.9	50
21	Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells. ACS Medicinal Chemistry Letters, 2014, 5, 782-786.	2.8	30
22	Eriodictyol-7-O-glucoside activates Nrf2 and protects against cerebral ischemic injury. Toxicology and Applied Pharmacology, 2013, 273, 672-679.	2.8	43
23	<scp>APP</scp> independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (<scp>RAP</scp>). Journal of Neurochemistry, 2013, 124, 123-132.	3.9	20
24	Neuroprotective effects of linarin through activation of the PI3K/Akt pathway in amyloid-Î²-induced neuronal cell death. Bioorganic and Medicinal Chemistry, 2011, 19, 4021-4027.	3.0	113
25	Î±-Synuclein binds the K_{ATP} channel at insulin-secretory granules and inhibits insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E276-E286.	3.5	71
26	Serine 129 Phosphorylation Reduces the Ability of Î±-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo. Journal of Biological Chemistry, 2010, 285, 17648-17661.	3.4	105
27	14-3-3Î¶ Contributes to Tyrosine Hydroxylase Activity in MN9D Cells. Journal of Biological Chemistry, 2009, 284, 14011-14019.	3.4	72
28	Rapid activation of ERK by 6â€hydroxydopamine promotes survival of dopaminergic cells. Journal of Neuroscience Research, 2008, 86, 108-117.	2.9	54
29	Î±-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neuroscience Letters, 2008, 435, 24-29.	2.1	91
30	Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. Journal of Neurochemistry, 2006, 99, 1188-1196.	3.9	93
31	Î±-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. Journal of Cell Science, 2005, 118, 3523-3530.	2.0	219
32	Could a loss of Î±â€synuclein function put dopaminergic neurons at risk?. Journal of Neurochemistry, 2004, 89, 1318-1324.	3.9	130
33	6â€hydroxydopamine induces dopaminergic cell degeneration via a caspaseâ€9â€mediated apoptotic pathway that is attenuated by caspaseâ€9dn expression. Journal of Neuroscience Research, 2004, 77, 747-761.	2.9	35
34	The endocytotic pathway is required for increased AÎ²42 secretion during apoptosis. Molecular Brain Research, 2004, 128, 201-211.	2.3	12
35	Effects of GDNF on 6â€OHDAâ€induced death in a dopaminergic cell line: Modulation by inhibitors of PI3 kinase and MEK. Journal of Neuroscience Research, 2003, 73, 105-112.	2.9	78
36	Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism and Related Disorders, 2002, 8, 389-393.	2.2	97

#	Article	IF	Citations
37	Regional distribution of DARPP-32 (Dopamine- 0Mr = 32,000) mRNA in mouse brain. Journal of Comparative Neurology, 1992, 318, 304-315.	1.6	25